Mirabegron

Definition

An orally bioavailable agonist of the human beta-3 adrenergic receptor (ADRB3), with muscle relaxing, neuroprotective and potential antineoplastic activities. Upon oral administration, mirabegron binds to and activates ADRB3, which leads to smooth muscle relaxation. Mirabegron also restores sympathetic stimulation in mesenchymal stem cell (MSC) niches, inhibits JAK2-mutated hematopoietic stem cell (HSC) expansion and blocks the progression of myeloproliferative neoplasms (MPNs). Lack of sympathetic stimulation of the MSC and HSC niche is associated with the development of MPNs.

Also known as 2-(2-Aminothiazol-4-yl)-N-[4-(2-{[(2R)-2-hydroxy-2-phenylethyl]amino}ethyl)phenyl] Acetamide, 4-Thiazoleacetamide, 2-Amino-N-(4-(2-(((2R)-2-hydroxy-2-phenylethyl)amino)ethyl)phenyl)-, Betanis, MIRABEGRON, Myrbetriq, YM-178, YM178 — per NCIT

Also identified as

• ATC G04BD12 per RXNORM
• NCIT NCIT:C90633 per NCIT
• SCTID 703803006 per RXNORM
• SCTID 703804000 per RXNORM
• UNII MVR3JL3B2V per RXNORM

Indications